KR100694735B1 - 일치환 및 이치환된 3-프로필 감마-아미노부티르산 - Google Patents

일치환 및 이치환된 3-프로필 감마-아미노부티르산 Download PDF

Info

Publication number
KR100694735B1
KR100694735B1 KR1020017015841A KR20017015841A KR100694735B1 KR 100694735 B1 KR100694735 B1 KR 100694735B1 KR 1020017015841 A KR1020017015841 A KR 1020017015841A KR 20017015841 A KR20017015841 A KR 20017015841A KR 100694735 B1 KR100694735 B1 KR 100694735B1
Authority
KR
South Korea
Prior art keywords
aminomethyl
methyl
acid
hexanoic acid
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020017015841A
Other languages
English (en)
Korean (ko)
Other versions
KR20020009631A (ko
Inventor
토마스 리차드 벨리오티
저스틴 스티븐 브라이언스
아이호에조 빅터 에카토
오거스틴 토비 오슈마
로버트 마이클 스켈쿤
앤드류 존 쏘르프
로렌스 데이비드 와이즈
데이비드 쥐르겐 우스트로우
포-와이 옌
제이콥 브래들리 슈와르츠
Original Assignee
워너-램버트 캄파니 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 워너-램버트 캄파니 엘엘씨 filed Critical 워너-램버트 캄파니 엘엘씨
Publication of KR20020009631A publication Critical patent/KR20020009631A/ko
Application granted granted Critical
Publication of KR100694735B1 publication Critical patent/KR100694735B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/08—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to hydrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/20—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/22—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated the carbon skeleton being further substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/30—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/32—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020017015841A 1999-06-10 2000-05-31 일치환 및 이치환된 3-프로필 감마-아미노부티르산 Expired - Fee Related KR100694735B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13848599P 1999-06-10 1999-06-10
US60/138,485 1999-06-10

Publications (2)

Publication Number Publication Date
KR20020009631A KR20020009631A (ko) 2002-02-01
KR100694735B1 true KR100694735B1 (ko) 2007-03-14

Family

ID=22482232

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020017015841A Expired - Fee Related KR100694735B1 (ko) 1999-06-10 2000-05-31 일치환 및 이치환된 3-프로필 감마-아미노부티르산

Country Status (43)

Country Link
EP (1) EP1192125B9 (https=)
JP (1) JP3904452B2 (https=)
KR (1) KR100694735B1 (https=)
CN (2) CN1196671C (https=)
AP (1) AP1397A (https=)
AR (1) AR033335A1 (https=)
AT (1) ATE419231T1 (https=)
AU (1) AU776723C (https=)
BG (1) BG65561B1 (https=)
BR (1) BR0011727A (https=)
CA (2) CA2374755C (https=)
CO (1) CO5200791A1 (https=)
CR (1) CR6529A (https=)
CU (1) CU23101A3 (https=)
CY (1) CY1108827T1 (https=)
CZ (2) CZ301608B6 (https=)
DE (1) DE60041256D1 (https=)
DK (1) DK1192125T3 (https=)
DZ (1) DZ3253A1 (https=)
EA (1) EA004398B1 (https=)
EE (1) EE200100672A (https=)
ES (1) ES2317839T3 (https=)
GE (1) GEP20074142B (https=)
HK (1) HK1046401B (https=)
HR (1) HRP20020025A2 (https=)
HU (1) HUP0201601A3 (https=)
IL (2) IL146969A0 (https=)
IS (1) IS6181A (https=)
MA (1) MA26804A1 (https=)
ME (1) MEP44808A (https=)
MX (1) MXPA01012319A (https=)
NO (2) NO327746B1 (https=)
NZ (1) NZ515668A (https=)
OA (1) OA11962A (https=)
PE (1) PE20010285A1 (https=)
PT (1) PT1192125E (https=)
RS (2) RS50352B (https=)
SI (1) SI1192125T1 (https=)
SK (2) SK287399B6 (https=)
TR (1) TR200103587T2 (https=)
UA (1) UA72519C2 (https=)
WO (1) WO2000076958A2 (https=)
ZA (1) ZA200109711B (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7164034B2 (en) 1999-06-10 2007-01-16 Pfizer Inc. Alpha2delta ligands for fibromyalgia and other disorders
US6620829B2 (en) 2000-10-17 2003-09-16 Warner-Lambert Company Method of treating noninflammatory cartilage damage
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
ATE540678T1 (de) * 2001-06-11 2012-01-15 Xenoport Inc Prodrugs aus gaba-analoga, zusammensetzungen und ihre verwendungen
ITMI20011308A1 (it) 2001-06-21 2002-12-21 Nicox Sa Farmaci per il dolore cronico
AU2003201716B2 (en) 2002-01-31 2008-04-17 Warner-Lambert Company Llc Alpha 2 delta ligands to treat tinnitus
NI200300043A (es) 2002-03-28 2003-11-05 Warner Lambert Co AMINOACIDOS CON AFINIDAD POR LA PROTEINA a2DELTA.
US20030225149A1 (en) 2002-04-30 2003-12-04 Blazecka Peter G. Process for preparing highly functionalized gamma-butyrolactams and gamma-amino acids
US7071339B2 (en) 2002-08-29 2006-07-04 Warner Lambert Company Llc Process for preparing functionalized γ-butyrolactones from mucohalic acid
WO2004054560A1 (en) 2002-12-13 2004-07-01 Warner-Lambert Company Llc Alpha-2-delta ligand to treat lower urinary tract symptoms
BR0317253A (pt) * 2002-12-13 2005-11-01 Warner Lambert Co Derivados pregabalina para o tratamento da fibromialgia e outras patologias
CA2451267A1 (en) 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
MXPA05006209A (es) * 2002-12-13 2005-08-19 Warner Lambert Co Pregabalina y sus derivados para el tratamiento de fibromialgia y otros trastornos relacionados.
ITMI20022658A1 (it) 2002-12-17 2004-06-18 Nicox Sa Farmaci per il dolore cronico.
WO2005002585A1 (en) * 2003-07-02 2005-01-13 Warner-Lambert Company Llc Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor
NZ545494A (en) 2003-09-12 2009-10-30 Pfizer Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors
BRPI0414781A (pt) * 2003-09-25 2006-11-21 Warner Lambert Co aminoácidos com afinidade para a proteìna (alfa)2(delta)
EP1670750A1 (en) 2003-09-25 2006-06-21 Warner-Lambert Company LLC Prodrugs of amino acids with affinity for the alpha2delta- protein
WO2006043171A2 (en) * 2004-10-23 2006-04-27 Warner-Lambert Company Llc Methods of using alpha2delta-1 selective compounds
WO2007031263A1 (en) * 2005-09-15 2007-03-22 Ucb Pharma, S.A. 4-substituted pyrr0lidin-2-0nes and their use
US20070141684A1 (en) 2005-12-21 2007-06-21 Pfizer Inc Preparation of gamma-amino acids having affinity for the alpha-2-delta protein
AR061728A1 (es) * 2006-06-30 2008-09-17 Pfizer Prod Inc Composicion para tratamiento usando compuestos selectivos alfa-2-delta-1
CA2673545A1 (en) 2006-12-22 2008-07-03 Recordati Ireland Limited Combination therapy of lower urinary tract disorders with .alpha.2.delta. ligands and nsaids
WO2009136375A1 (en) * 2008-05-08 2009-11-12 Pfizer Inc Treatment of interstitial cystitis
EP2509596B1 (en) 2009-12-08 2019-08-28 Case Western Reserve University Gamma aminoacids for treating ocular disorders
CN101914031B (zh) * 2010-07-30 2013-08-28 中国广州分析测试中心 普瑞巴林衍生物及其应用
HUE061437T2 (hu) * 2015-10-23 2023-06-28 Navitor Pharm Inc A Sestrin-GATOR2 kölcsönhatás modulátorai és ezek alkalmazásai
US10912750B2 (en) 2017-04-26 2021-02-09 Navitor Pharmaceuticals, Inc. Modulators of Sestrin-GATOR2 interaction and uses thereof
CN113164414A (zh) 2018-10-24 2021-07-23 纳维托制药有限公司 多晶型化合物和其用途
CA3156436A1 (en) 2019-11-01 2021-05-06 Steven LEVENTER Methods of treatment using an mtorc1 modulator

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992009560A1 (en) * 1990-11-27 1992-06-11 Northwestern University Gaba and l-glutamic acid analogs for antiseizure treatment

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2460891C2 (de) * 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US4087544A (en) * 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
US6197819B1 (en) * 1990-11-27 2001-03-06 Northwestern University Gamma amino butyric acid analogs and optical isomers
JP3856816B2 (ja) * 1992-05-20 2006-12-13 ノースウェスターン ユニヴァーシティ 抗発作治療用のｇａｂａ及びｌ−グルタミン酸類縁体
US5637767A (en) * 1995-06-07 1997-06-10 Warner-Lambert Company Method of making (S)-3-(aminomethyl)-5-methylhexanoic acid
IL126999A (en) * 1996-07-24 2002-03-10 Warner Lambert Co Pharmaceutical preparations containing isobutylgaba and its history for use in the treatment of pain
ATE361909T1 (de) * 1996-10-23 2007-06-15 Warner Lambert Co Substituierte gamma-aminobuttersäurederivate als arzneimittel
ATE323067T1 (de) * 1997-10-27 2006-04-15 Warner Lambert Co Zyklische aminosäuren und deren derivate als arzneimittel

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992009560A1 (en) * 1990-11-27 1992-06-11 Northwestern University Gaba and l-glutamic acid analogs for antiseizure treatment

Also Published As

Publication number Publication date
UA72519C2 (en) 2005-03-15
TR200103587T2 (tr) 2002-04-22
CZ20014285A3 (cs) 2002-07-17
DE60041256D1 (de) 2009-02-12
IL146969A (en) 2008-03-20
CN1355784A (zh) 2002-06-26
ES2317839T3 (es) 2009-05-01
RS50352B (sr) 2009-11-10
ZA200109711B (en) 2003-03-20
HK1046401A1 (en) 2003-01-10
EP1192125B9 (en) 2009-09-16
CZ300834B6 (cs) 2009-08-19
WO2000076958A2 (en) 2000-12-21
CZ301608B6 (cs) 2010-04-28
CA2374755C (en) 2010-03-30
PT1192125E (pt) 2009-03-05
WO2000076958A3 (en) 2001-04-12
EP1192125A2 (en) 2002-04-03
DZ3253A1 (fr) 2000-12-21
SK17642001A3 (sk) 2002-10-08
EE200100672A (et) 2003-02-17
PL352431A1 (en) 2003-08-25
SK287247B6 (sk) 2010-04-07
YU87001A (sh) 2004-07-15
CU23101A3 (es) 2005-12-20
AU5311900A (en) 2001-01-02
HUP0201601A3 (en) 2002-11-28
DK1192125T3 (da) 2009-02-16
CA2374755A1 (en) 2000-12-21
BR0011727A (pt) 2002-03-05
NO20015949D0 (no) 2001-12-05
CO5200791A1 (es) 2002-09-27
CY1108827T1 (el) 2014-04-09
NO327746B1 (no) 2009-09-14
HRP20020025A2 (en) 2003-12-31
SI1192125T1 (sl) 2009-04-30
BG65561B1 (bg) 2008-12-30
HUP0201601A2 (en) 2002-10-28
EP1192125B1 (en) 2008-12-31
SK287399B6 (sk) 2010-08-09
GEP20074142B (en) 2007-07-10
NZ515668A (en) 2004-02-27
JP2003502308A (ja) 2003-01-21
RS20090257A (sr) 2010-03-02
ATE419231T1 (de) 2009-01-15
CA2689997A1 (en) 2000-12-21
HK1076626A1 (en) 2006-01-20
AP2002002388A0 (en) 2002-03-31
AR033335A1 (es) 2003-12-17
CN1196671C (zh) 2005-04-13
JP3904452B2 (ja) 2007-04-11
CR6529A (es) 2003-11-25
MA26804A1 (fr) 2004-12-20
NO20015949L (no) 2001-12-05
EA200101134A1 (ru) 2002-06-27
IL146969A0 (en) 2002-08-14
CN1310872C (zh) 2007-04-18
KR20020009631A (ko) 2002-02-01
MEP44808A (en) 2011-02-10
AU776723B2 (en) 2004-09-16
AU776723C (en) 2005-06-02
AP1397A (en) 2005-04-19
PE20010285A1 (es) 2001-03-22
MXPA01012319A (es) 2002-07-22
CN1660779A (zh) 2005-08-31
OA11962A (en) 2006-04-17
EA004398B1 (ru) 2004-04-29
HK1046401B (zh) 2005-12-02
BG106292A (bg) 2002-05-31
IS6181A (is) 2001-11-28
NO20091094L (no) 2001-12-05

Similar Documents

Publication Publication Date Title
KR100694735B1 (ko) 일치환 및 이치환된 3-프로필 감마-아미노부티르산
US6642398B2 (en) Mono-and disubstituted 3-propyl gamma-aminobutyric acids
JP3744928B2 (ja) 医薬製剤としての２環式アミノ酸
KR20010043831A (ko) 칼슘 채널의 알파2델타 서브유닛에 대한 친화력이 있는구조적으로 한정된 아미노산 화합물
ZA200100837B (en) Branched alkyl pyrrolidine-3-carboxylic acids.
US7179934B2 (en) Amino acids with affinity for the α2δ-protein
US20040186177A1 (en) Alpha2delta ligands for fibromyalgia and other disorders
AU2003303040B2 (en) Pregabalin derivatives for the treatment of fibromyalgia and other disorders
EP1840117A1 (en) Mono- and disubstituted 3-propyl gamma-aminobutyric acids
PL203443B1 (pl) Monopodstawiony kwas 3-propylo- ?-aminomas lowy, kompozycja farmaceutyczna zawieraj aca ten zwi azek i zastosowanie
OA12897A (en) Mono-and disubstituted 3-propyl gamma-aminobutyricacids.
OA12543A (en) Mono-and disubstituted 3-propyl gamma-aminobutyricacids.

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

FPAY Annual fee payment

Payment date: 20100122

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20110308

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20110308

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000